264 related articles for article (PubMed ID: 25947165)
41. A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.
de Barra E; Hodgson SH; Ewer KJ; Bliss CM; Hennigan K; Collins A; Berrie E; Lawrie AM; Gilbert SC; Nicosia A; McConkey SJ; Hill AV
PLoS One; 2014; 9(12):e115161. PubMed ID: 25522180
[TBL] [Abstract][Full Text] [Related]
42. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.
Dudareva M; Andrews L; Gilbert SC; Bejon P; Marsh K; Mwacharo J; Kai O; Nicosia A; Hill AV
Vaccine; 2009 Jun; 27(27):3501-4. PubMed ID: 19464527
[TBL] [Abstract][Full Text] [Related]
43. Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.
Hodgson SH; Choudhary P; Elias SC; Milne KH; Rampling TW; Biswas S; Poulton ID; Miura K; Douglas AD; Alanine DG; Illingworth JJ; de Cassan SC; Zhu D; Nicosia A; Long CA; Moyle S; Berrie E; Lawrie AM; Wu Y; Ellis RD; Hill AVS; Draper SJ
Mol Ther; 2014 Dec; 22(12):2142-2154. PubMed ID: 25156127
[TBL] [Abstract][Full Text] [Related]
44. Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants.
Bliss CM; Drammeh A; Bowyer G; Sanou GS; Jagne YJ; Ouedraogo O; Edwards NJ; Tarama C; Ouedraogo N; Ouedraogo M; Njie-Jobe J; Diarra A; Afolabi MO; Tiono AB; Yaro JB; Adetifa UJ; Hodgson SH; Anagnostou NA; Roberts R; Duncan CJ; Cortese R; Viebig NK; Leroy O; Lawrie AM; Flanagan KL; Kampmann B; Imoukhuede EB; Sirima SB; Bojang K; Hill AV; Nébié I; Ewer KJ
Mol Ther; 2017 Feb; 25(2):547-559. PubMed ID: 28153101
[TBL] [Abstract][Full Text] [Related]
45. Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.
Elias SC; Choudhary P; de Cassan SC; Biswas S; Collins KA; Halstead FD; Bliss CM; Ewer KJ; Hodgson SH; Duncan CJ; Hill AV; Draper SJ
Immunology; 2014 Apr; 141(4):628-44. PubMed ID: 24303947
[TBL] [Abstract][Full Text] [Related]
46. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial.
de Graaf H; Payne RO; Taylor I; Miura K; Long CA; Elias SC; Zaric M; Minassian AM; Silk SE; Li L; Poulton ID; Baker M; Draper SJ; Gbesemete D; Brendish NJ; Martins F; Marini A; Mekhaiel D; Edwards NJ; Roberts R; Vekemans J; Moyle S; Faust SN; Berrie E; Lawrie AM; Hill F; Hill AVS; Biswas S
Front Immunol; 2021; 12():694759. PubMed ID: 34335606
[TBL] [Abstract][Full Text] [Related]
47. Tailoring a Combination Preerythrocytic Malaria Vaccine.
Bauza K; Atcheson E; Malinauskas T; Blagborough AM; Reyes-Sandoval A
Infect Immun; 2015 Dec; 84(3):622-34. PubMed ID: 26667840
[TBL] [Abstract][Full Text] [Related]
48. Liver-Directed AAV8 Booster Vaccine Expressing
Shahnaij M; Iyori M; Mizukami H; Kajino M; Yamagoshi I; Syafira I; Yusuf Y; Fujiwara K; Yamamoto DS; Kato H; Ohno N; Yoshida S
Front Immunol; 2021; 12():612910. PubMed ID: 34248928
[TBL] [Abstract][Full Text] [Related]
49. Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation.
Flanagan KL; Plebanski M; Odhiambo K; Sheu E; Mwangi T; Gelder C; Hart K; Kortok M; Lowe B; Robson KJ; Marsh K; Hill AV
Am J Trop Med Hyg; 2006 Mar; 74(3):367-75. PubMed ID: 16525093
[TBL] [Abstract][Full Text] [Related]
50. Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria.
Halbroth BR; Sebastian S; Salman AM; Ulaszewska M; Gola A; Longley RJ; Janse CJ; Khan SM; Hill AVS; Spencer AJ
Infect Immun; 2020 Jan; 88(2):. PubMed ID: 31740525
[TBL] [Abstract][Full Text] [Related]
51. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.
Elias SC; Collins KA; Halstead FD; Choudhary P; Bliss CM; Ewer KJ; Sheehy SH; Duncan CJ; Biswas S; Hill AV; Draper SJ
J Immunol; 2013 Feb; 190(3):1135-47. PubMed ID: 23293353
[TBL] [Abstract][Full Text] [Related]
52. A Prime/Boost PfCS14K
Vijayan A; Mejías-Pérez E; Espinosa DA; Raman SC; Sorzano COS; Zavala F; Esteban M
Clin Vaccine Immunol; 2017 May; 24(5):. PubMed ID: 28298290
[TBL] [Abstract][Full Text] [Related]
53. Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors.
Atcheson E; Bauza K; Salman AM; Alves E; Blight J; Viveros-Sandoval ME; Janse CJ; Khan SM; Hill AVS; Reyes-Sandoval A
Infect Immun; 2018 Sep; 86(9):. PubMed ID: 29986894
[TBL] [Abstract][Full Text] [Related]
54. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.
Gilbert SC; Moorthy VS; Andrews L; Pathan AA; McConkey SJ; Vuola JM; Keating SM; Berthoud T; Webster D; McShane H; Hill AV
Vaccine; 2006 May; 24(21):4554-61. PubMed ID: 16150517
[TBL] [Abstract][Full Text] [Related]
55. Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain.
Spencer AJ; Cottingham MG; Jenks JA; Longley RJ; Capone S; Colloca S; Folgori A; Cortese R; Nicosia A; Bregu M; Hill AV
PLoS One; 2014; 9(6):e100538. PubMed ID: 24945248
[TBL] [Abstract][Full Text] [Related]
56. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
Moorthy VS; McConkey S; Roberts M; Gothard P; Arulanantham N; Degano P; Schneider J; Hannan C; Roy M; Gilbert SC; Peto TE; Hill AV
Vaccine; 2003 May; 21(17-18):1995-2002. PubMed ID: 12706689
[TBL] [Abstract][Full Text] [Related]
57. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.
Walther M; Thompson FM; Dunachie S; Keating S; Todryk S; Berthoud T; Andrews L; Andersen RF; Moore A; Gilbert SC; Poulton I; Dubovsky F; Tierney E; Correa S; Huntcooke A; Butcher G; Williams J; Sinden RE; Hill AV
Infect Immun; 2006 May; 74(5):2706-16. PubMed ID: 16622207
[TBL] [Abstract][Full Text] [Related]
58. Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.
Dejon-Agobe JC; Ateba-Ngoa U; Lalremruata A; Homoet A; Engelhorn J; Nouatin OP; Edoa JR; Fernandes JF; Esen M; Mouwenda YD; Betouke Ongwe EM; Massinga-Loembe M; Hoffman SL; Sim BKL; Theisen M; Kremsner PG; Adegnika AA; Lell B; Mordmüller B
Clin Infect Dis; 2019 Sep; 69(8):1377-1384. PubMed ID: 30561539
[TBL] [Abstract][Full Text] [Related]
59. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.
Tamminga C; Sedegah M; Maiolatesi S; Fedders C; Reyes S; Reyes A; Vasquez C; Alcorta Y; Chuang I; Spring M; Kavanaugh M; Ganeshan H; Huang J; Belmonte M; Abot E; Belmonte A; Banania J; Farooq F; Murphy J; Komisar J; Richie NO; Bennett J; Limbach K; Patterson NB; Bruder JT; Shi M; Miller E; Dutta S; Diggs C; Soisson LA; Hollingdale MR; Epstein JE; Richie TL
Hum Vaccin Immunother; 2013 Oct; 9(10):2165-77. PubMed ID: 23899517
[TBL] [Abstract][Full Text] [Related]
60. A viral vectored prime-boost immunization regime targeting the malaria Pfs25 antigen induces transmission-blocking activity.
Goodman AL; Blagborough AM; Biswas S; Wu Y; Hill AV; Sinden RE; Draper SJ
PLoS One; 2011; 6(12):e29428. PubMed ID: 22216279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
